Table 2.
Characteristics of the included clinical studies
| Study | Country | Year | Enrollment | MSI / MMR | Intervention Strategy | Primary outcome measures | Research status | Results |
|---|---|---|---|---|---|---|---|---|
| ChiCTR2100046768 | China | 2021 | 20 | MSS/pMMR | FMTplus tislelizumab and fruquintinib | ORR DCR | Recruiting | YES[32] |
| NCT05279677 | China | 2022 | 30 | MSS/pMMR | FMT + PD-1 ICIs + Sintilimab Injection + Fruquintinib | ORR | Recruiting | NO |
| NCT04729322 | China | 2021 | 15 | dMMR | Pembrolizumab/Nivolumab + FMT | ORR | Recruiting | NO |
| ChiCTR2100052431 | China | 2021 | — | MSI-H/dMMR | FMT + PD-1 ICIs | ORR PFS OS | Active, not recruiting | NO |
| NCT04130763 | China | 2019 | 10 | — | FMT + PD-1 ICIs | ORR | Recruiting | NO |